source
- FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancerSummit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
- Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firmsSofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…